Replies to post #450 on Fate Therapeutics Inc (FATE)

[jondoeuk]

Yes, and while FT819 exhibited similar expansion to auto CAR-T's cells, had shortened persistence. Adding the ADR (+/- additional KOs, such as CD54/58) should help overcome the latter, but I still think they need to improve differentiation protocols, engineering, selection, CAR constructs, expansion, and formulation (high Tscm (+/- Tcm) phenotype(s)). The goal should be best-in-class products.

Long-term, look to add CD4+ https://ashpublications.org/blood/article/134/Supplement_1/1937/428148/Guided-Polarization-of-iPSC-Derived-CD4SP-Helper-T